Patrick M. Honore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrick M. Honore has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Bruno Pirenne
1 shared publicationD. Valadi
1 shared publicationElisabeth De Waele
Intensive Care Dept,Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
1 shared publicationGenevieve Hanique
1 shared publication- Herbert D. Spapen
Department of Intensive Care, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium
1 shared publication James R. Matson
1 shared publication
Latest Publications
- 10 October 2012
- Published by Elsevier in Journal of Critical Care
- Vol. 27 (5) , 514-515
Fractional excretion of urea to differentiate transient from persistent acute kidney injury: Should we still trust old tools in the biomarker era?
- 10 October 2012
- Published by Elsevier in Journal of Critical Care
- Vol. 27 (5) , 514-515
Fractional excretion of urea to differentiate transient from persistent acute kidney injury: Should we still trust old tools in the biomarker era?
- 1 December 2004
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 27 (12) , 1077-1082
High Volume Hemofiltration (HVHF) in Sepsis: A Comprehensive Review of Rationale, Clinical Applicability, Potential Indications and Recommendations for Future Research
HVHF can be still seen as a potent powerful immunomodulatory treatment in sepsis. Pleiotropical properties of HVHF give this treatment the possibility to affect not only SIRS but also cardiovascular compounds, clotting and post septic-insult immunoparalysis. By this multimodal approach, HVHF can alter the sepsis network through many targets. The crucial relationship between immunological changes, hemodynamics and survival must be found in future prospective randomised studies. Circulatory cytokines are no longer valuable players except for catecholamine-resistant septic shock. Definitions are of upmost value as ultrafiltrate volume has been correlated in terms of response and survival with the type of disease (sepsis or not) and severity (catecholamine-resistant shock or not). This latter condition can be seen as the best indication for HVHF and probably even more for very high volume hemofiltration (VHVHF). More studies are needed to clarify the role of HVHF in hyperdynamic septic shock (with or without acute renal failure), sepsis and SIRS. They can be seen as potential indications up to now. Possible interferences with activated protein C deserve more attention as both treatments can be given sequentially in the same septic patient or even concomitantly.
- 1 December 2004
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 27 (12) , 1077-1082
High Volume Hemofiltration (HVHF) in Sepsis: A Comprehensive Review of Rationale, Clinical Applicability, Potential Indications and Recommendations for Future Research
HVHF can be still seen as a potent powerful immunomodulatory treatment in sepsis. Pleiotropical properties of HVHF give this treatment the possibility to affect not only SIRS but also cardiovascular compounds, clotting and post septic-insult immunoparalysis. By this multimodal approach, HVHF can alter the sepsis network through many targets. The crucial relationship between immunological changes, hemodynamics and survival must be found in future prospective randomised studies. Circulatory cytokines are no longer valuable players except for catecholamine-resistant septic shock. Definitions are of upmost value as ultrafiltrate volume has been correlated in terms of response and survival with the type of disease (sepsis or not) and severity (catecholamine-resistant shock or not). This latter condition can be seen as the best indication for HVHF and probably even more for very high volume hemofiltration (VHVHF). More studies are needed to clarify the role of HVHF in hyperdynamic septic shock (with or without acute renal failure), sepsis and SIRS. They can be seen as potential indications up to now. Possible interferences with activated protein C deserve more attention as both treatments can be given sequentially in the same septic patient or even concomitantly.
- 1 October 2001
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 29 (10) , 1903-1909
Effects of normothermia versus hypothermia on extravascular lung water and serum cytokines during cardiopulmonary bypass: A randomized, controlled trial
To evaluate the influence of perfusion temperature on the systemic effects of cardiopulmonary bypass (CPB), including extravascular lung water index (EVLWI), and serum cytokines. Prospective, randomized, controlled study. Cardiothoracic intensive care unit of a university hospital. Patients undergoing elective coronary artery bypass grafting. Twenty-one patients undergoing elective coronary artery bypass grafting were randomly assigned to receive either normothermic bypass (36°C, n = 8) with intermittent antegrade warm blood cardioplegia (IAWBC), or hypothermic (32°C, n = 13) CPB with cold crystalloid cardioplegia. Mean arterial pressure, heart rate, cardiac output, systemic vascular resistance, mean pulmonary arterial pressure, and pulmonary vascular resistance were determined at baseline, i.e., after induction of anesthesia but before sternal opening (T−1), at arrival in the intensive care unit (T0), and 4 hrs (T4), 8 hrs (T8), and 24 hrs (T24) after surgery. EVLWI, intrathoracic blood volume index (ITBVI), and EVLW/ITBV ratio were obtained by using thermal dye dilution utilizing an arterial thermistor-tipped fiberoptic catheter and were recorded at T−1, T0, T4, T8, and T24. Serial blood samples for cytokine measurements were obtained at each hemodynamic measurement time point. Before, during, and after CPB, there were no differences in the conventional hemodynamic measurements between the groups. There were no changes in EVLWI up to T8 in either group. Furthermore, no change in the ratio EVLW/ITBW was observed between the groups at any time, further indicating the absence of a change in pulmonary permeability. Plasma levels of interleukin-6, tumor necrosis factor-α, and interleukin-10 increased during and after CPB, independently of the perfusion temperature. Normothermic CPB is not associated with additional inflammatory and related systemic adverse effects regarding cytokine production and EVLWI as compared with mild hypothermia. The potential temperature-dependent release of cytokines and subsequent inflammation has not been observed and normothermic CPB may be seen as a safe technique regarding this issue.
- 1 October 2001
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 29 (10) , 1903-1909
Effects of normothermia versus hypothermia on extravascular lung water and serum cytokines during cardiopulmonary bypass: A randomized, controlled trial
To evaluate the influence of perfusion temperature on the systemic effects of cardiopulmonary bypass (CPB), including extravascular lung water index (EVLWI), and serum cytokines. Prospective, randomized, controlled study. Cardiothoracic intensive care unit of a university hospital. Patients undergoing elective coronary artery bypass grafting. Twenty-one patients undergoing elective coronary artery bypass grafting were randomly assigned to receive either normothermic bypass (36°C, n = 8) with intermittent antegrade warm blood cardioplegia (IAWBC), or hypothermic (32°C, n = 13) CPB with cold crystalloid cardioplegia. Mean arterial pressure, heart rate, cardiac output, systemic vascular resistance, mean pulmonary arterial pressure, and pulmonary vascular resistance were determined at baseline, i.e., after induction of anesthesia but before sternal opening (T−1), at arrival in the intensive care unit (T0), and 4 hrs (T4), 8 hrs (T8), and 24 hrs (T24) after surgery. EVLWI, intrathoracic blood volume index (ITBVI), and EVLW/ITBV ratio were obtained by using thermal dye dilution utilizing an arterial thermistor-tipped fiberoptic catheter and were recorded at T−1, T0, T4, T8, and T24. Serial blood samples for cytokine measurements were obtained at each hemodynamic measurement time point. Before, during, and after CPB, there were no differences in the conventional hemodynamic measurements between the groups. There were no changes in EVLWI up to T8 in either group. Furthermore, no change in the ratio EVLW/ITBW was observed between the groups at any time, further indicating the absence of a change in pulmonary permeability. Plasma levels of interleukin-6, tumor necrosis factor-α, and interleukin-10 increased during and after CPB, independently of the perfusion temperature. Normothermic CPB is not associated with additional inflammatory and related systemic adverse effects regarding cytokine production and EVLWI as compared with mild hypothermia. The potential temperature-dependent release of cytokines and subsequent inflammation has not been observed and normothermic CPB may be seen as a safe technique regarding this issue.
- 1 November 2000
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 28 (11) , 3581-3587
Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock
To evaluate the effects of short-term, high-volume hemofiltration (STHVH) on hemodynamic and metabolic status and 28-day survival in patients with refractory septic shock. Prospective, interventional. Intensive care unit (ICU), tertiary institution. Twenty patients with intractable cardiocirculatory failure complicating septic shock, who had failed to respond to conventional therapy. STHVH, followed by conventional continuous venovenous hemofiltration. STHVH consisted of a 4-hr period during which 35 L of ultrafiltrate is removed and neutral fluid balance is maintained. Subsequent conventional continuous venovenous hemofiltration continued for at least 4 days. Cardiac index, systemic vascular resistance, pulmonary vascular resistance, oxygen delivery, mixed venous oxygen saturation, arterial pH, and lactate were measured serially. Fluid and inotropic support were managed by protocol. Therapeutic endpoints were as follows during STHVH: a) by 2 hrs, a ≥50% increase in cardiac index; b) by 2 hrs, a ≥25% increase in mixed venous saturation; c) by 4 hrs, an increase in arterial pH to >7.3; d) by 4 hrs, a ≥50% reduction in epinephrine dose. Patients who attained all four goals (11 of 20) were considered hemodynamic “responders”; patients who did not (9 of 20) were considered hemodynamic “nonresponders.” There were no differences in baseline hemodynamic, metabolic, and Acute Physiology and Chronic Health Evaluation and Simplified Acute Physiology Scores between responders and nonresponders. Survival to 28 days was better among responders (9 of 11 patients) than among nonresponders (0 of 9). Factors associated with survival were hemodynamic-metabolic response status, time interval from ICU admission to initiation of STHVH, and body weight. These data suggest that STHVH may be of major therapeutic value in the treatment of intractable cardiocirculatory failure complicating septic shock. Early initiation of therapy and adequate dose may improve hemodynamic and metabolic responses and 28-day survival.
- 1 November 2000
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 28 (11) , 3581-3587
Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock
To evaluate the effects of short-term, high-volume hemofiltration (STHVH) on hemodynamic and metabolic status and 28-day survival in patients with refractory septic shock. Prospective, interventional. Intensive care unit (ICU), tertiary institution. Twenty patients with intractable cardiocirculatory failure complicating septic shock, who had failed to respond to conventional therapy. STHVH, followed by conventional continuous venovenous hemofiltration. STHVH consisted of a 4-hr period during which 35 L of ultrafiltrate is removed and neutral fluid balance is maintained. Subsequent conventional continuous venovenous hemofiltration continued for at least 4 days. Cardiac index, systemic vascular resistance, pulmonary vascular resistance, oxygen delivery, mixed venous oxygen saturation, arterial pH, and lactate were measured serially. Fluid and inotropic support were managed by protocol. Therapeutic endpoints were as follows during STHVH: a) by 2 hrs, a ≥50% increase in cardiac index; b) by 2 hrs, a ≥25% increase in mixed venous saturation; c) by 4 hrs, an increase in arterial pH to >7.3; d) by 4 hrs, a ≥50% reduction in epinephrine dose. Patients who attained all four goals (11 of 20) were considered hemodynamic “responders”; patients who did not (9 of 20) were considered hemodynamic “nonresponders.” There were no differences in baseline hemodynamic, metabolic, and Acute Physiology and Chronic Health Evaluation and Simplified Acute Physiology Scores between responders and nonresponders. Survival to 28 days was better among responders (9 of 11 patients) than among nonresponders (0 of 9). Factors associated with survival were hemodynamic-metabolic response status, time interval from ICU admission to initiation of STHVH, and body weight. These data suggest that STHVH may be of major therapeutic value in the treatment of intractable cardiocirculatory failure complicating septic shock. Early initiation of therapy and adequate dose may improve hemodynamic and metabolic responses and 28-day survival.